What question did this study set out to answer?

To develop a standardized, validated, and reproducible tool for grading the magnitude of clinical benefit anticipated from new anti-cancer therapies.

May 31, 2015Annals of OncologyOpen Access

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

View Full Paper

Ask AI

Bookmark

Authors

NCNathan I. ChernyShaare Zedek Medical Center RSRichard SullivanKing's College London UDUrania DafniNational and Kapodistrian University of Athens

Discussion

Member takes

Implication

Methodological report demonstrates a standardized benefit scale across anti-cancer therapies, highlighting a consistent framework for cost-effective oncology care.

Key Points

To develop a standardized, validated, and reproducible tool for grading the magnitude of clinical benefit anticipated from new anti-cancer therapies.
Designed a structured and generic framework—the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS)—to evaluate efficacy, survival, and safety outcomes from phase III randomized trials.
Established reproducible criteria to stratify therapeutic clinical benefit ranging from marginal progression-free survival gains to substantial overall survival improvements, incorporating periodic revisions.
Formulated a validated scale providing a relative ranking of clinically meaningful benefit achievable with novel anti-cancer treatments.
Created a standardized policy and clinical guidance mechanism to distinguish true therapeutic breakthroughs from minor incremental gains to support affordable, value-driven cancer care.

Cite This Study

Cherny et al. (2015) studied this question.

synapsesocial.com/papers/6a7053372163a0a01bc48c4f https://doi.org/10.1093/annonc/mdv249

View Full Paper

Ask AI

Bookmark

Implication

Methodological report demonstrates a standardized benefit scale across anti-cancer therapies, highlighting a consistent framework for cost-effective oncology care.

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

Discussion

Member takes

Implication

Key Points

Cite This Study

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider